Clinical trials
Nasopharyngeal Carcinoma clinical trials
Below are recruiting nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 163 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT06636734RecruitingPhase 2
Lovastatin plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
Atlanta, GeorgiaAges 18 years+ - NCT06532279RecruitingPhase 2
Testing BMX-001 with chemoradiation for head and neck cancer
This trial tests whether adding BMX-001 (a drug that may protect healthy tissues) to standard chemoradiation can reduce side effects and improve outcomes for people with head and neck cancer. It's a randomized study, so you would have a 50/50 chance of getting BMX-001 or a placebo.
Gilbert, ArizonaAges 18 years+ - NCT06509009RecruitingPhase 2
Nimotuzumab and TGP for first-line recurrent / metastatic nasopharyngeal cancer
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06323239RecruitingPhase 2
Radiation plus chemo and immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06277050RecruitingPhase 3
Toripalimab and capecitabine after chemo-radiation for high-risk nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
Ganzhou, JiangxiAges 18–70 - NCT06093061RecruitingPhase 2
Maintenance therapy for high-risk nasopharyngeal cancer
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
SingaporeAges 21–99 - NCT06064097RecruitingPhase 2
Nivolumab plus chemo for young people with nasopharyngeal cancer
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Birmingham, AlabamaAges Up to 21 years - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT05587543RecruitingEarly Phase 1
Test of EBV CAR-T or TCR-T cells for nasopharyngeal cancer
This early-phase study tests personalized immune cells (EBV CAR-T or TCR-T) to treat nasopharyngeal cancer that has returned or spread. It aims to help the immune system find and attack the cancer after other treatments have not worked.
ShanghaiAges 18–75 - NCT04944914RecruitingPhase 3
Camrelizumab with targeted radiation for limited nasopharyngeal cancer spread
This trial tests whether combining camrelizumab (an immune medicine) with stereotactic body radiotherapy (high-precision radiation) works better than camrelizumab alone. It’s for people whose nasopharyngeal cancer has spread to a small number of spots in the body and may help control those metastases longer.
Guangzhou, GuangdongAges 18–70 - NCT03010150Recruiting
Blood tests and swallowing exercise check-ins for head and neck cancer
This study looks at whether giving swallowing exercises and checking in with questionnaires can help people with metastatic (spreading to neck lymph nodes) head and neck cancers do the exercises correctly. It also uses blood tests to better understand adherence and progress over time.
Houston, TexasAges 18 years+ - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT04376866RecruitingPhase 3
Immunotherapy for repeat nasopharyngeal cancer after it returns
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
Nanning, GuangxiAges 18–65 - NCT05447169Recruiting
Testing blood and DNA checks for nasopharyngeal cancer risk
This study tests an Epstein-Barr virus (EBV) blood antibody and an EBV DNA test to help screen people at higher risk for nasopharyngeal cancer. It may find signs earlier in certain families where cancer runs.
Guangzhou, GuangdongAges 30–62 - NCT07412314Recruiting
Proton Therapy for Recurrent Nasopharyngeal Cancer
This trial uses proton therapy (a precise type of radiation) to treat people whose nasopharyngeal cancer has come back. It aims to see if this treatment can help control the cancer while limiting side effects.
Guangzhou, GuangdongAges 18 years+ - NCT06886347RecruitingPhase 1
New treatment for metastatic nasopharyngeal cancer before chemotherapy
This trial tests a new treatment for people with advanced nasopharyngeal cancer that has spread (stage IVb) and who have not yet had chemotherapy. It aims to see if the experimental treatment is safe and effective as a first option.
Hangzhou, ZhejiangAges 18–75 - NCT07277764RecruitingPhase 2
Radiation and immunotherapy for returning nasopharyngeal cancer
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Nanchang, JiangxiAges 18–75 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT05062005RecruitingPhase 3
Tests two ways of treating locally advanced nasopharyngeal cancer
This phase 3 trial compares a standard treatment plan (CRT) versus a new approach (ICCRT) for people with locally advanced nasopharyngeal cancer, without spread to distant organs. It aims to see which plan works better and is safe for tumors in the head and neck area.
Guangzhou, GuangdongAges 18–65 - NCT05860868RecruitingPhase 3
Two versus three chemo treatments before radiation for nasopharyngeal cancer
This Phase 3 trial compares giving two cycles versus three cycles of chemotherapy before other treatment for locally advanced nasopharyngeal cancer. It may help find which schedule works best to control the cancer while managing side effects.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT07177443RecruitingPhase 3
Immunotherapy with chemo and radiation for nasopharyngeal cancer
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–65 - NCT04425265Recruiting
Low-temperature plasma treatment vs high-frequency cautery for recurring cancer
This trial compares two ways of surgically treating localized, recurrent nasopharyngeal cancer: a low-temperature plasma radiofrequency method versus a standard high-frequency cautery method. You might be eligible if your recurrence is limited and can be surgically removed, and you are within the allowed health and age ranges.
Guangzhou, GuangdongAges 18–70 - NCT03907826RecruitingPhase 3
PD-1 therapy plus chemoradiation for recurrent nasopharyngeal cancer
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
Guangzhou, GuangdongAges 18–70
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 163 recruiting nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Nasopharyngeal Carcinoma (NPC)
- Locally Advanced Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma AJCC v8
- Metastatic Nasopharyngeal Carcinoma
- Stage III Nasopharyngeal Carcinoma AJCC v8
- Nasopharyngeal Carcinoma by AJCC V8 Stage
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.